Foamix Pharmaceuticals (FOMX) PT Set at $12.00 by HC Wainwright

HC Wainwright set a $12.00 target price on Foamix Pharmaceuticals (NASDAQ:FOMX) in a research report report published on Tuesday. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other equities analysts have also commented on the stock. Cantor Fitzgerald started coverage on shares of Foamix Pharmaceuticals in a research report on Thursday, October 11th. They set an overweight rating for the company. Zacks Investment Research upgraded shares of Foamix Pharmaceuticals from a hold rating to a buy rating and set a $5.75 price objective for the company in a research report on Wednesday, September 19th. BidaskClub lowered shares of Foamix Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, October 9th. Cowen set a $30.00 price objective on shares of Foamix Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, November 7th. Finally, ValuEngine lowered shares of Foamix Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, October 4th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. Foamix Pharmaceuticals has a consensus rating of Hold and an average target price of $13.94.

Shares of NASDAQ:FOMX opened at $4.09 on Tuesday. Foamix Pharmaceuticals has a fifty-two week low of $3.60 and a fifty-two week high of $7.60.

Foamix Pharmaceuticals (NASDAQ:FOMX) last issued its earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.07). Foamix Pharmaceuticals had a negative return on equity of 118.29% and a negative net margin of 2,049.92%. The company had revenue of $0.87 million for the quarter, compared to the consensus estimate of $1.10 million. Equities analysts forecast that Foamix Pharmaceuticals will post -1.67 earnings per share for the current fiscal year.

In other Foamix Pharmaceuticals news, Director Aharon Schwartz acquired 12,200 shares of the stock in a transaction on Wednesday, November 28th. The stock was acquired at an average price of $3.88 per share, for a total transaction of $47,336.00. Following the completion of the transaction, the director now directly owns 50,000 shares of the company’s stock, valued at $194,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 11,967 shares of company stock valued at $49,967 in the last quarter. 3.30% of the stock is owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. ARK Investment Management LLC raised its stake in shares of Foamix Pharmaceuticals by 17.7% in the 2nd quarter. ARK Investment Management LLC now owns 106,243 shares of the specialty pharmaceutical company’s stock valued at $532,000 after purchasing an additional 15,980 shares during the period. Citadel Advisors LLC raised its stake in shares of Foamix Pharmaceuticals by 3,281.1% in the 2nd quarter. Citadel Advisors LLC now owns 501,621 shares of the specialty pharmaceutical company’s stock valued at $2,513,000 after purchasing an additional 486,785 shares during the period. Senzar Asset Management LLC acquired a new stake in shares of Foamix Pharmaceuticals in the 2nd quarter valued at about $338,000. Orbimed Advisors LLC raised its stake in shares of Foamix Pharmaceuticals by 223.2% in the 2nd quarter. Orbimed Advisors LLC now owns 4,040,000 shares of the specialty pharmaceutical company’s stock valued at $20,240,000 after purchasing an additional 2,790,000 shares during the period. Finally, First Manhattan Co. raised its stake in shares of Foamix Pharmaceuticals by 1,664.3% in the 3rd quarter. First Manhattan Co. now owns 617,500 shares of the specialty pharmaceutical company’s stock valued at $3,538,000 after purchasing an additional 582,500 shares during the period. Institutional investors and hedge funds own 62.84% of the company’s stock.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus.

Further Reading: Can individual investors take part in an IPO?

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply